# A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

> **NCT03936777** · PHASE3 · COMPLETED · sponsor: **Zogenix, Inc.** · enrollment: 412 (actual)

## Conditions studied

- Dravet Syndrome
- Lennox Gastaut Syndrome
- Epileptic Encephalopathy

## Interventions

- **DRUG:** ZX008 (Fenfluramine Hydrochloride)

## Key facts

- **NCT ID:** NCT03936777
- **Lead sponsor:** Zogenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-22
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-05-08
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2025-11-17

## Collaborators

- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936777, "A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03936777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*